What question did this study set out to answer?

To determine the incidence of mutant EGFRvIII expression in head and neck squamous cell carcinoma and assess its functional role in tumor growth, chemotherapy response, and anti-EGFR therapy resistance.

September 1, 2006Clinical Cancer ResearchOpen Access

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

View Full Paper

Ask AI

Bookmark

Authors

JSJohn C. SokUniversity of Pittsburgh FCFrancesca M Coppelli STSufi M. ThomasUniversity of New Mexico

Discussion

Member takes

Implication

Preclinical study demonstrates that mutant EGFRvIII promotes tumor growth and blunts cetuximab response in head and neck cancer, suggesting dual-targeting therapies could improve outcomes.

Key Points

To determine the incidence of mutant EGFRvIII expression in head and neck squamous cell carcinoma and assess its functional role in tumor growth, chemotherapy response, and anti-EGFR therapy resistance.
Evaluated 33 head and neck squamous cell carcinoma (HNSCC) tumor specimens for EGFRvIII expression using immunostaining and reverse transcription-PCR.
Stably transfected a representative HNSCC cell line with an EGFRvIII expression construct or empty vector control.
Assessed in vitro proliferation, in vivo tumor growth, cisplatin-induced apoptosis, and growth inhibition following treatment with the anti-EGFR antibody cetuximab (C225).
EGFRvIII expression was identified in 42% of HNSCC tumors, where it consistently co-occurred with wild-type EGFR.
Cells expressing EGFRvIII exhibited increased proliferation rates in vitro and increased tumor volumes in vivo relative to vector-transfected controls.
EGFRvIII-transfected cells showed decreased apoptosis in response to cisplatin and reduced growth inhibition following cetuximab treatment compared with control cells.

Cite This Study

Sok et al. (2006) studied this question.

synapsesocial.com/papers/6a70dc8bce524a4339c48c8b https://doi.org/10.1158/1078-0432.ccr-06-0913

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates that mutant EGFRvIII promotes tumor growth and blunts cetuximab response in head and neck cancer, suggesting dual-targeting therapies could improve outcomes.

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Discussion

Member takes

Implication

Key Points

Cite This Study

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider